A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma.
Oestrogen receptors have been demonstrated in pancreatic adenocarcinoma and it has been suggested that tamoxifen increases patient survival. This study of 14 patients with unresectable carcinoma of the pancreas fails to demonstrate any objective response from endocrine manipulation using tamoxifen.